S'abonner

Longitudinal atopic dermatitis control and persistence vary with timing of disease onset in children: A cohort study - 09/11/19

Doi : 10.1016/j.jaad.2019.05.016 
Joy Wan, MD, MSCE a, b, , Nandita Mitra, PhD c, d, Ole J. Hoffstad, MA c, Albert C. Yan, MD b, David J. Margolis, MD, PhD a, c, d
a Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 
b Section of Pediatric Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 
c Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 
d Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 

Correspondence to: Joy Wan, MD, MSCE, 3400 Civic Center Blvd, PCAM South Tower, 7th Floor, Office 775, Philadelphia, PA 19104.3400 Civic Center Blvd, PCAM South Tower, 7th Floor, Office 775PhiladelphiaPA19104

Abstract

Background

Wide variation exists in the timing of atopic dermatitis (AD) disease onset among children. Distinct trajectories of early-onset, mid-onset, and late-onset AD have been previously described.

Objective

To evaluate longitudinal disease control and persistence with respect to age at onset of AD.

Methods

A cohort study was performed using the Pediatric Eczema Elective Registry, a prospective observational cohort of subjects with childhood-onset AD. AD control and persistence were assessed biannually for up to 10 years.

Results

A total of 8015 subjects with 41,934 person-years of follow-up were included. In longitudinal analyses using generalized linear latent and mixed modeling, older age at onset of AD was associated with better disease control and less-persistent AD. For each additional year of age at onset of AD, the adjusted odds ratios for poorer AD control and for persistent AD were 0.93 (95% confidence interval, 0.91-0.94) and 0.84 (95% confidence interval, 0.80-0.88), respectively. Differences in AD control and persistence among subjects with early-, mid-, and late-onset AD were most pronounced from early adolescence onward.

Limitations

Misclassification bias may arise from using self-reported data on age at onset. Attrition and missing data in longitudinal studies may introduce bias.

Conclusion

Early-, mid-, and late-onset pediatric AD appear to be clinically distinct subtypes of the disease.

Le texte complet de cet article est disponible en PDF.

Key words : atopic dermatitis, disease control, disease persistence, early onset, eczema, epidemiology, late onset, prognosis

Abbreviations used : aOR, AD, CI, IQR, PEER


Plan


 Funding sources: Supported in part by grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant T32-AR007465 [to Dr Wan]) and a Dermatology Foundation Dermatologist Investigator Research Fellowship (to Dr Wan). The data source used in this study is the Pediatric Eczema Elective Registry, which is a study funded by Valeant Pharmaceuticals through a grant to Dr Margolis. No funding sources had a role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the article; or decision to submit the article for publication.
 Disclosure: Dr Wan receives research fellowship funding from Pfizer Inc (to the Trustees of the University of Pennsylvania) and has received payment for consulting work with Health Union LLC. Dr Margolis has served on advisory committees for Sanofi/Regeneron and Pfizer Inc. Dr Yan has served as a consultant to Sanofi/Regeneron, Pfizer Inc, Procter and Gamble, and Ortho Dermatologics/Valeant. Dr Mitra and Mr Hoffstad have no conflicts of interest to disclose.
 Reprints not available from the authors.


© 2019  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 81 - N° 6

P. 1292-1299 - décembre 2019 Retour au numéro
Article précédent Article précédent
  • Chronologic order of appearance of immune-mediated inflammatory diseases relative to diagnosis of psoriasis
  • Yuki M.F. Andersen, Jashin J. Wu, Jacob P. Thyssen, Alexander Egeberg
| Article suivant Article suivant
  • Diverse presentations of cutaneous mosaicism occur in CYLD cutaneous syndrome and may result in parent-to-child transmission
  • Majid Arefi, Valerie Wilson, Siobhan Muthiah, Simon Zwolinski, Dalvir Bajwa, Paul Brennan, Katie Blasdale, David Bourn, John Burn, Mauro Santibanez-Koref, Neil Rajan

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.